title: Hairy cell leukemia: short review, today's recommendations and outlook.
abstract: Hairy cell leukemia (HCL) is part of the low-grade non-Hodgkin lymphoma family and represents approximately 2% of all leukemias. Treatment with splenectomy and interferon-α historically belonged to the first steps of therapeutic options, achieving partial responses/remissions (PR) in most cases with a median survival between 4 and 6 years in the 1980s. The introduction of the purine analogs (PA) pentostatin and cladribine made HCL a well-treatable disease: overall complete response rates (CRR) range from 76 to 98%, with a median disease-free survival (DFS) of 16 years a normal lifespan can be reached and HCL-related deaths are rare. However, insufficient response to PA with poorer prognosis and relapse rates of 30-40% after 5-10 years of follow-up may require alternative strategies. Minimal residual disease can be detected by additional examinations of bone marrow specimens after treatment with PA. The use of immunotherapeutic monoclonal antibodies (mAB) like rituximab as a single agent or in combination with a PA or more recently clinical trials with recombinant immunotoxins (RIT) show promising results to restrict these problems. Recently, the identification of the possible disease-defining BRAF V600E mutation may allow the development of new therapeutic targets.
authors: Center for Integrated Oncology (CIO), Bonn, Germany.
authors: V
authors: V
authors: Maevis
authors: Kantonsspital Graubünden, Chur, Switzerland.
authors: U
authors: U
authors: Mey
authors: Center for Integrated Oncology (CIO), Bonn, Germany.
authors: G
authors: G
authors: Schmidt-Wolf
authors: Center for Integrated Oncology (CIO), Bonn, Germany.
authors: I G H
authors: IG
authors: Schmidt-Wolf